Norovirus Treatment Market Outlook 2025: Opportunities and Emerging Challenges

 Save 20% on All Global Market Reports With Code ONLINE20 — Gain Insights Into Tariffs, Inflation, and Industry Trends

 

 What Are the Key Factors Driving Norovirus Treatment Market Size and Growth?
 The norovirus treatment market size has grown rapidly in recent years. It will grow from $1.75 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to rising global norovirus outbreaks, an increase in public awareness, a growing focus on supportive care, investment in vaccine research, improving healthcare infrastructure, and heightened demand for effective infection control measures.
 
 The norovirus treatment market size is expected to see rapid growth in the next few years. It will grow to $2.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing funding for antiviral drug development, rising adoption of rapid diagnostic tools, growing awareness of norovirus-related public health impacts, expanding healthcare access in emerging economies, and the development of novel supportive therapies targeting symptom severity. Major trends in the forecast period include advancements in vaccine development, innovative antiviral therapies, improved molecular diagnostic technologies, adoption of AI-driven diagnostic tools, enhanced public health campaigns, and development of cost-effective point-of-care treatment solutions.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24629&type=smp
 
 Who Are the Major Contributors to the Norovirus Treatment Market Growth?
 The increasing prevalence of infectious disease is expected to propel the growth of the norovirus treatment market going forward. Infectious diseases are illnesses caused by bacteria, viruses, fungi, or parasites that spread between people and include influenza, tuberculosis, HIV/AIDS, malaria, and norovirus. Infectious disease is increasing due to urban overcrowding, which facilitates faster transmission of pathogens among densely packed populations. Norovirus treatment helps reduce the impact of infectious disease by managing symptoms effectively and limiting the spread through proper hydration, hygiene, and isolation practices. For instance, in March 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, an estimated 10.8 million individuals, comprising 6.0 million men, 3.6 million women, and 1.3 million children, contracted tuberculosis globally in 2023. Therefore, the increasing prevalence of infectious disease is driving growth of the norovirus treatment market.
 
 How Is the Norovirus Treatment Market Divided by Type and Application?
 The norovirus treatment market covered in this report is segmented — 
 
 1) By Treatment: Electrolytes, Intravenous Fluids, Antipyretics, Analgesics, Anti-Diarrheal, Other Treatments 
 2) By Diagnosis: Bacteria Culture Test, Stool Tests, Other Diagnosis 
 3) By Route Of Administration: Oral, Intravenous, Subcutaneous 
 4) By End User: Hospitals, Clinics, Homecare Settings
 
 Subsegments:
 1) By Electrolytes: Oral Rehydration Salts (ORS), Sports Drinks, Pediatric Electrolyte Solutions
 2) By Intravenous Fluids: Crystalloids, Colloids, Lactated Ringer’s Solution 
 3) By Antipyretics: Acetaminophen (Paracetamol), Ibuprofen, Aspirin
 4) By Analgesics: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioid Analgesics, Acetaminophen-Based Analgesics
 5) By Anti-Diarrheal: Loperamide, Bismuth Subsalicylate, Diphenoxylate-Atropine
 6) By Other Treatments: Antiemetics, Probiotics, Zinc Supplements
 
 What Are the Emerging Market Trends That Companies Should Monitor in Norovirus Treatment Market?
 Major companies operating in the norovirus treatment market are focusing on developing innovative solutions, such as advanced mRNA vaccines, to accelerate the development of targeted immunization, enhance protection against severe infections, and reduce the global burden of norovirus-related illnesses. Advanced mRNA vaccines are next-generation immunizations that use specially engineered messenger RNA to instruct cells to produce specific proteins, triggering a targeted immune response with improved stability, efficacy, and adaptability against various infectious diseases. For instance, in October 2024, Moderna Inc., a US-based biotechnology company, partnered with the UK Health Security Agency (UKHSA), a UK-based government agency, and launched the world’s first Phase 3 trial of an mRNA norovirus vaccine (mRNA-1403) in the UK. This trial introduces a vaccine designed to target the highly contagious norovirus by instructing the body to produce viral proteins that stimulate a strong immune response without using the live virus. Unique features of the launch include its use of stabilized mRNA for improved durability, rapid development potential in response to evolving strains, and the ability to induce both antibody and T-cell responses.
 
 Who Are the Emerging Players in the Norovirus Treatment Market?
 Major companies operating in the norovirus treatment market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, AstraZeneca plc, GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Reckitt Benckiser Group plc, Sun Pharmaceutical Industries Ltd., Lupin Ltd., Aurobindo Pharma Limited, Cipla Inc., Endo International plc. 
 
 Get the full norovirus treatment market report here:
 https://www.thebusinessresearchcompany.com/report/norovirus-treatment-global-market-report
 
 How Is Regional Performance Expected to Affect Norovirus Treatment Market Growth?
 North America was the largest region in the norovirus treatment market in 2024. The regions covered in the norovirus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company